{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:24Z","timestamp":1790240604517,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025NSFJQ0063"],"award-info":[{"award-number":["2025NSFJQ0063"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYYC25004"],"award-info":[{"award-number":["ZYYC25004"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejso.2026.112137","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:17:19Z","timestamp":1789453039000},"page":"112137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of adjuvant therapy in non-pCR patients after neoadjuvant chemoimmunotherapy: Comparison with neoadjuvant chemoradiotherapy for ESCC"],"prefix":"10.1016","volume":"52","author":[{"given":"Yuhao","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinhao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-1965","authenticated-orcid":false,"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejso.2026.112137_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice Guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.ejso.2026.112137_bib2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jtcvs.2022.08.009","article-title":"Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: results from the phase III trial NEOCRTEC5010","volume":"165","author":"Chen","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"18","key":"10.1016\/j.ejso.2026.112137_bib3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol : Official J Am Soc Clinical Oncol"},{"issue":"6382","key":"10.1016\/j.ejso.2026.112137_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, NY)"},{"issue":"10294","key":"10.1016\/j.ejso.2026.112137_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.ejso.2026.112137_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"10302","key":"10.1016\/j.ejso.2026.112137_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.ejso.2026.112137_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112137_bib9","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ (Clinical research ed)"},{"issue":"3","key":"10.1016\/j.ejso.2026.112137_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ejso.2026.112137_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.112137_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112137_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejso.2026.112137_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2026.112137_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","article-title":"Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma","volume":"160","author":"Guo","year":"2025","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12967-025-06672-3","article-title":"Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezac341","article-title":"The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer","volume":"62","author":"Xiao","year":"2022","journal-title":"Eur J Cardio Thorac Surg : Official J Eur Ass Cardio-Thoracic Surgery"},{"issue":"2","key":"10.1016\/j.ejso.2026.112137_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2023.12.030","article-title":"Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","volume":"168","author":"Yu","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","article-title":"Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"169","author":"Yang","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"13","key":"10.1016\/j.ejso.2026.112137_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2026.112137_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112137_bib23","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1158\/1078-0432.CCR-20-3215","article-title":"Inflammation mediates the development of aggressive breast cancer following radiotherapy","volume":"27","author":"Ma","year":"2021","journal-title":"Clin Cancer Res : an official journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.ejso.2026.112137_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/bjc.2017.175","article-title":"Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy","volume":"117","author":"Gash","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib25","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1038\/s41467-025-59865-1","article-title":"Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejso.2026.112137_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:24:47Z","timestamp":1790238287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326007560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0748798326007560"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112137","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of adjuvant therapy in non-pCR patients after neoadjuvant chemoimmunotherapy: Comparison with neoadjuvant chemoradiotherapy for ESCC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112137"}}